COE Details

Centre of Excellence (CoE) in the Novel Drug Delivery Systems (NDDS) is being establish at NIPER Raebareli with the support from DoP, MoC&F, GoI initiative “Promotion of Research and Innovations in Pharma Med Tech (PRIP)”. The goal of PRIP scheme is to transform Indian Pharmaceutical sector from cost based to the innovation based. As of now the drug delivery systems against the various diseases are not only costly but also had poor patient compliance. CoE at NIPER Raebareli is being established to tackle and overcome the limitations associated with the existing drug delivery systems and to innovate new drug delivery technologies. CoE at NIPER Raebareli will not merely a CoE towards development in the novel drug delivery systems but also a nodal centre to foster the consultancy, contract research, and industry collaboration to take academic research to the market. The state of art research and analytical facility built under CoE and NIPER Raebareli will serve as bridge between academia and industry to translate research to the market.

NIPER Raebareli research engages in diverse and multidisciplinary area spanning synthesis of novel therapeutics (medicinal chemistry), formulations (pharmaceutics), pharmacological and toxicological profiling (Pharmacology and toxicology) and regulatory toxicology. Department of biotechnology serving as added benefits to NIPER Raebareli research in exploring biological and molecular aspects of therapeutics. Recently started program Medical Devices at NIPER Raebareli will be playing a pivotal role in the developing cost effective and robust drug delivery systems. CoE, NIPER Raebareli will be serving a junction point where research work from different domains of Pharmaceutical Science and biotechnology will be translated towards precise and effective means of NDDS. Considering NIPER Raebareli research areas CoE has been established in designing novel pharmaceutical formulations with the potential for translational research, including highlighting the pitfalls therein. Subsequently, CoE is facility available for the biocompatibility and toxicological profiling of these formulations to ensure that the principles of green nanotechnology/circular pharmaceutical economy are implemented. CoE will also suggest inputs for the policies required for sustainable growth of the NDDS sector in India. CoE is functioning as an independent organization under Section 8 company compliant with the Indian Companies Act.